Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBTROZI vs BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
IBTROZI is a Fabry disease therapeutic, a recombinant human alpha-galactosidase A enzyme that catalyzes the hydrolysis of globotriaosylceramide (GL-3) to reduce its accumulation in tissues.
Brompheniramine is a first-generation antihistamine that competitively inhibits histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and nasal decongestion. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist that suppresses the cough reflex in the medulla oblongata.
Fabry disease
Symptomatic relief of upper respiratory symptoms associated with allergic rhinitis, common cold, or sinusitis including nasal congestion, rhinorrhea, sneezing, and cough.
150 mg orally twice daily for 4 weeks, followed by 100 mg orally twice daily for 2 weeks, with food.
Adults and children ≥12 years: 1 tablet (brompheniramine maleate 4 mg, pseudoephedrine HCl 60 mg, dextromethorphan HBr 15 mg) orally every 4 hours, not to exceed 4 tablets in 24 hours, or 2 tablets (extended-release) every 12 hours, not to exceed 4 tablets in 24 hours.
Terminal elimination half-life is 12–14 hours in patients with normal renal function; prolonged to 24–36 hours in moderate renal impairment (Cr Cl <60 m L/min), requiring dose adjustment
Brompheniramine: 12-34 hours (mean ~24 h), prolonged in hepatic impairment. Pseudoephedrine: 5-8 hours (p H-dependent urinary excretion; alkaline urine prolongs half-life). Dextromethorphan: 3-4 hours (extensive metabolizers) or 18-24 hours (poor metabolizers of CYP2D6).
Metabolized by catabolic pathways into small peptides and amino acids.
Brompheniramine: extensively metabolized via hepatic CYP450 (CYP2D6, CYP3A4) to desmethylbrompheniramine and other metabolites. Pseudoephedrine: partially metabolized via N-demethylation (CYP450) to norgseudoephedrine; 43-96% excreted unchanged. Dextromethorphan: primarily metabolized via CYP2D6 to dextrorphan (active), also via CYP3A4/5 to 3-methoxymorphinan.
Approximately 70% renal (unchanged drug), 20% biliary/fecal (conjugates and metabolites), 10% other
Brompheniramine: Renal (approx. 80% as metabolites, <1% unchanged). Pseudoephedrine: Renal (70-90% unchanged, rest as metabolites). Dextromethorphan: Renal (primarily as metabolites, <1% unchanged). Biliary/fecal: Minor for all three.
97% bound primarily to albumin; minor binding to α1-acid glycoprotein (3%)
Brompheniramine: 60-80% (primarily albumin, alpha-1-acid glycoprotein). Pseudoephedrine: <10% (negligible). Dextromethorphan: 50-60% (possibly to albumin).
0.45 L/kg (range 0.3–0.6 L/kg); indicates moderate distribution into total body water, with limited tissue binding
Brompheniramine: 7-10 L/kg (large, due to extensive tissue distribution). Pseudoephedrine: 2.5-3.5 L/kg (moderate, distributes into body water). Dextromethorphan: 3-5 L/kg (moderate, distributed to tissues including brain).
Oral: 85% (range 75–95%); reduced to 60% when administered with high-fat meal (increased first-pass metabolism)
Brompheniramine: ~70% (oral). Pseudoephedrine: 90-100% (oral). Dextromethorphan: ~10-30% (oral, due to extensive first-pass metabolism; in poor metabolizers, bioavailability higher).
Cr Cl 30-59 m L/min: 100 mg twice daily for 4 weeks then 75 mg twice daily for 2 weeks; Cr Cl 15-29 m L/min: 75 mg twice daily for 4 weeks then 50 mg twice daily for 2 weeks; Cr Cl <15 m L/min or on dialysis: not recommended.
GFR ≥30 m L/min: No adjustment. GFR 10-29 m L/min: Administer every 6 hours; monitor for CNS effects. GFR <10 m L/min: Avoid use (risk of toxicity from pseudoephedrine and dextromethorphan accumulation).
Child-Pugh A or B: no dose adjustment; Child-Pugh C: not recommended.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce frequency (e.g., every 6 hours) and monitor for CNS depression. Child-Pugh C: Avoid use (dextromethorphan metabolism reduced; brompheniramine may accumulate).
Weight <50 kg: 3 mg/kg (maximum 150 mg) orally twice daily for 4 weeks, then 2 mg/kg (maximum 100 mg) twice daily for 2 weeks; Weight ≥50 kg: same as adult dosing.
Children 6-11 years: 1/2 tablet (brompheniramine maleate 2 mg, pseudoephedrine HCl 30 mg, dextromethorphan HBr 7.5 mg) orally every 4 hours, not to exceed 4 doses in 24 hours. Children 2-5 years: Not recommended (safety and efficacy not established). Children <2 years: Contraindicated (risk of respiratory depression).
No specific dose adjustment recommended; monitor renal function and adjust based on Cr Cl.
Elderly >65 years: Initiate at lowest effective dose (e.g., 1/2 tablet) every 6-8 hours due to increased anticholinergic effects, hypotension, and CNS excitation. Maximum: 2 tablets in 24 hours. Monitor for confusion, urinary retention, and elevated blood pressure.
No FDA boxed warnings reported.
None.
Hypersensitivity reactions including anaphylaxis,Infusion-associated reactions,Potential for immune complex formation and immune-mediated reactions
Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias, especially in patients with pre-existing heart disease or hyperthyroidism.,CNS depression: avoid concurrent use with alcohol or other sedatives; may impair mental/physical abilities.,Serotonin syndrome: risk with concomitant serotonergic drugs including MAOIs, SSRIs, SNRIs, triptans, linezolid, methylene blue.,QT prolongation: caution with drugs that prolong QT interval or predisposing conditions (e.g., electrolyte abnormalities, bradycardia).,Anticholinergic effects: caution in patients with glaucoma, prostatic hypertrophy, urinary retention, or asthma.,Inhibition of CYP2D6: dextromethorphan may increase levels of CYP2D6 substrates (e.g., TCAs, antipsychotics).
History of life-threatening hypersensitivity to the active substance or any excipients
Hypersensitivity to any component,Concurrent use or within 14 days of MAO inhibitors (hypertensive crisis),Severe hypertension or coronary artery disease,Narrow-angle glaucoma,Urinary retention,During or immediately after treatment with serotonergic drugs (risk of serotonin syndrome)
Avoid grapefruit, grapefruit juice, and Seville oranges (contain CYP3A4 inhibitors). High-fat meals do not significantly affect absorption.
Avoid alcohol, which may potentiate CNS depression. Limit caffeine intake (coffee, tea, cola) as pseudoephedrine may increase stimulant effects. High-tyramine foods (e.g., aged cheese, cured meats, fermented products) may cause hypertensive crisis if combined with MAOIs, but this combination is contraindicated. No other significant food interactions.
IBTROZI is contraindicated in pregnancy due to known teratogenicity. First trimester: High risk of major congenital malformations (neural tube defects, craniofacial anomalies). Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Effective contraception required during treatment and for 1 month after last dose.
Brompheniramine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Pseudoephedrine: Case-control studies suggest small increased risk of gastroschisis and hemifacial microsomia with first-trimester use; vasoconstriction may reduce uteroplacental blood flow in third trimester. Dextromethorphan: No human teratogenicity data; animal studies show no fetal harm at therapeutic doses. Overall, combination is not recommended in first trimester; avoid in third trimester due to pseudoephedrine effects.
No human data on presence in breast milk. M/P ratio unknown. Due to potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during treatment and for 1 month after last dose.
Brompheniramine: excreted in breast milk in small amounts; may cause infant irritability or drowsiness. Pseudoephedrine: concentrated in breast milk (M/P ratio ~3.0); may reduce milk production. Dextromethorphan: likely excreted in breast milk but no data on infant levels. Avoid during breastfeeding due to potential infant CNS effects and reduced milk supply.
No dose adjustment recommended as drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) are not applicable due to contraindication.
No specific dose adjustments studied for combination in pregnancy. Due to increased plasma volume and clearance, standard adult doses may be less effective; however, avoid use in pregnancy due to risks. No PK studies available.
IBTROZI (ibutropinib) is a selective BTK inhibitor used in relapsed/refractory mantle cell lymphoma. Monitor for atrial fibrillation and bleeding events, especially in patients on anticoagulants. Dose adjustments required for hepatic impairment (Child-Pugh B/C). Concomitant use with strong CYP3A4 inhibitors increases exposure; reduce dose by 50%.
Do not use in children under 6 years due to risk of respiratory depression from dextromethorphan. Avoid in patients with hypertension or coronary artery disease due to pseudoephedrine. Brompheniramine has pronounced anticholinergic effects; use cautiously in elderly or those with glaucoma, urinary retention, or BPH. For severe cough, dextromethorphan efficacy is limited; consider if nonproductive cough is disruptive. Maximum duration of treatment is 7 days; prolonged use may lead to rebound congestion and dependence.
Take IBTROZI exactly as prescribed, with or without food. Swallow capsule whole; do not crush or chew.,Avoid grapefruit, grapefruit juice, and Seville oranges as they increase drug levels and risk of side effects.,Report any signs of infection, unusual bruising or bleeding, or irregular heartbeat to your healthcare provider immediately.,Use effective contraception during treatment and for at least 1 month after the last dose, as IBTROZI can cause fetal harm.,Do not breastfeed while taking IBTROZI and for at least 2 weeks after the last dose.
Do not take more than 6 doses in 24 hours. Do not exceed 7 days of use without consulting a doctor.,Avoid alcohol and other CNS depressants (e.g., sedatives, tranquilizers) as they may increase drowsiness.,Do not use if you have taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.,Stop use and ask a doctor if symptoms do not improve within 7 days, are accompanied by fever, or if cough persists with headache, rash, or persistent headache.,Take with a full glass of water. May cause drowsiness; avoid driving or operating heavy machinery until you know how this medication affects you.,For the decongestant effect, take the last dose of the day several hours before bedtime to minimize insomnia.,Shake suspension well before use. Use only the dosing device provided.
No interactions on record
"Brompheniramine, a first-generation antihistamine, may inhibit the hepatic metabolism of sulfamethoxazole, a sulfonamide antibiotic, via competitive inhibition of cytochrome P450 enzymes, particularly CYP2C9. This results in elevated plasma concentrations of sulfamethoxazole, potentially increasing the risk of dose-dependent adverse effects such as hypersensitivity reactions, crystalluria, and hematologic toxicity (e.g., agranulocytosis). Clinically, patients may present with prolonged or intensified drug effects, including increased bone marrow suppression and renal impairment, especially in those with pre-existing hepatic or renal dysfunction."
"Dextropropoxyphene, an opioid analgesic, and brompheniramine, a first-generation antihistamine with anticholinergic properties, can synergistically depress the central nervous system (CNS) and respiratory centers. This interaction increases the risk of profound sedation, respiratory depression, coma, and death, particularly in elderly patients or those with pre-existing respiratory or hepatic impairment. Concurrent use also amplifies anticholinergic adverse effects such as urinary retention, constipation, and cognitive dysfunction."
"Brompheniramine, a first-generation antihistamine with significant central nervous system (CNS) depressant properties, can potentiate the CNS depressant effects of brimonidine, an alpha-2 adrenergic agonist used for ocular hypertension and glaucoma. This interaction leads to additive sedation, drowsiness, and dizziness, which may impair cognitive and motor function, increasing the risk of falls and accidents. Severe cases could result in excessive CNS depression, including somnolence and respiratory depression, particularly in elderly patients or those with compromised hepatic function."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBTROZI vs BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, answered by our medical review team.
IBTROZI is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by IBTROZI is a Fabry disease therapeutic, a recombinant human alpha-galactosidase A enzyme that catalyzes the hydrolysis of globotriaosylceramide (GL-3) to reduce its accumulation in tissues.. BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE is a Sympathomimetic that works by Brompheniramine is a first-generation antihistamine that competitively inhibits histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and nasal decongestion. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist that suppresses the cough reflex in the medulla oblongata.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBTROZI and BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBTROZI is: 150 mg orally twice daily for 4 weeks, followed by 100 mg orally twice daily for 2 weeks, with food.. The standard adult dose of BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE is: Adults and children ≥12 years: 1 tablet (brompheniramine maleate 4 mg, pseudoephedrine HCl 60 mg, dextromethorphan HBr 15 mg) orally every 4 hours, not to exceed 4 tablets in 24 hours, or 2 tablets (extended-release) every 12 hours, not to exceed 4 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBTROZI and BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBTROZI is classified as Category C. IBTROZI is contraindicated in pregnancy due to known teratogenicity. First trimester: High risk of major congenital malformations (neural tube defects, craniofacial anomalies). Sec. BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE is classified as Category A/B. Brompheniramine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Pseudoephedrine: Case-control studies suggest small increased risk of gastr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.